Major and modified nucleosides as markers in ovarian cancer: a pilot study

A number of major and modified nucleosides were measured in urine samples of patients with ovarian cancer. The patients were divided into three groups based on histological criteria: benign, borderline, malignant. 44% of the measured marker levels of the benign group were in the normal range, whereas 97% of the borderline and malignant groups were outside the normal range. After a total hysterectomy with adnexectomy and omentectomy in a patient with a borderline type malignancy, six of the seven elevated markers decreased to normal values.